Florence Laigle-Donadey1, François Doz, Jean-Yves Delattre. 1. Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière - APHP, Département d'Oncologie Pédiatrique, Institut Curie and Faculté de Médecine Paris V René Descartes, France. florence.laigle-donadey@psl.aphp.fr
Abstract
PURPOSE OF REVIEW: The purpose of this review is to determine if recent advances in diagnostic and treatment modalities result in improvement in the pattern of care of brainstem gliomas. RECENT FINDINGS: New MRI techniques may contribute to differential diagnosis and aid neurosurgeons in removing resectable brainstem tumors. A better radiological analysis of these heterogeneous tumors improves their classification and helps to better distinguish prognosis subgroups. However, biopsy remains indicated in many contrast enhancing brainstem masses in adults because of the great variety of differential diagnosis. SUMMARY: Diffuse brainstem glioma is the most common subtype of brainstem tumor and remains a devastating malignancy in children. Conventional radiotherapy is the standard of care and chemotherapy has been disappointing to date. Given the lack of efficacy of conventional drugs, a better understanding of the biology of this tumor is the key to more targeted therapy.
PURPOSE OF REVIEW: The purpose of this review is to determine if recent advances in diagnostic and treatment modalities result in improvement in the pattern of care of brainstem gliomas. RECENT FINDINGS: New MRI techniques may contribute to differential diagnosis and aid neurosurgeons in removing resectable brainstem tumors. A better radiological analysis of these heterogeneous tumors improves their classification and helps to better distinguish prognosis subgroups. However, biopsy remains indicated in many contrast enhancing brainstem masses in adults because of the great variety of differential diagnosis. SUMMARY: Diffuse brainstem glioma is the most common subtype of brainstem tumor and remains a devastating malignancy in children. Conventional radiotherapy is the standard of care and chemotherapy has been disappointing to date. Given the lack of efficacy of conventional drugs, a better understanding of the biology of this tumor is the key to more targeted therapy.
Authors: Kenneth J Cohen; Richard L Heideman; Tianni Zhou; Emiko J Holmes; Robert S Lavey; Eric Bouffet; Ian F Pollack Journal: Neuro Oncol Date: 2011-02-22 Impact factor: 12.300
Authors: Katherine A Zukotynski; Frederic H Fahey; Mehmet Kocak; Abass Alavi; Terence Z Wong; S Ted Treves; Barry L Shulkin; Daphne A Haas-Kogan; Jeffrey R Geyer; Sridhar Vajapeyam; James M Boyett; Larry E Kun; Tina Young Poussaint Journal: J Nucl Med Date: 2011-01-13 Impact factor: 10.057
Authors: Jasia Mahdi; Amish C Shah; Aimee Sato; Stephanie M Morris; Robert C McKinstry; Robert Listernick; Roger J Packer; Michael J Fisher; David H Gutmann Journal: Neurology Date: 2017-03-22 Impact factor: 9.910
Authors: Michelle Monje; Siddhartha S Mitra; Morgan E Freret; Tal B Raveh; James Kim; Marilyn Masek; Joanne L Attema; Gordon Li; Terri Haddix; Michael S B Edwards; Paul G Fisher; Irving L Weissman; David H Rowitch; Hannes Vogel; Albert J Wong; Philip A Beachy Journal: Proc Natl Acad Sci U S A Date: 2011-03-01 Impact factor: 11.205
Authors: Kristin A Bradley; Tianni Zhou; Rene Y McNall-Knapp; Regina I Jakacki; Adam S Levy; Gilbert Vezina; Ian F Pollack Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-22 Impact factor: 7.038
Authors: Yasser Bayoumi; Abdulrahman J Sabbagh; Reham Mohamed; Usama M ElShokhaiby; Ahmed Marzouk Maklad; Mutahir A Tunio; Ali Abdullah O Balbaid Journal: World J Clin Oncol Date: 2014-12-10
Authors: Amar Gajjar; Roger J Packer; N K Foreman; Kenneth Cohen; Daphne Haas-Kogan; Thomas E Merchant Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167